MM

Mitesh Mahendra Senghani

Active Director Additional Director DIN 11230126
DIN 11230126 First appointment Aug 2025 Primary industry Chemicals
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Mitesh Mahendra Senghani

Data last updated:

Mitesh Mahendra Senghani is an Additional Director at Zydrose Pharma Private Limited (since 2025). The company operates in Chemicals.

DIN 11230126
Primary Designation Additional Director
Industry Chemicals
First Appointment 24 Aug 2025

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Zydrose Pharma Private Limited U20119MH2025PTC448272
Additional Director24 Aug 2025Active

Board colleagues of Mitesh Mahendra Senghani

NameDINCompanyDesignation
Hetal Dhaval Shah09790816Zydrose Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Zydrose Pharma Private Limited
Premium access

Shareholding and investment profile for Mitesh Mahendra Senghani

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Mitesh Mahendra Senghani

Mitesh Mahendra Senghani currently holds 1 directorship: Zydrose Pharma Private Limited (Additional Director, since 24 Aug 2025).

Mitesh Mahendra Senghani was first appointed on 24 Aug 2025 as Additional Director at Zydrose Pharma Private Limited.

The current boards of Mitesh Mahendra Senghani's companies include Hetal Dhaval Shah (Zydrose Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available